Role of the TomoTherapy® System in the Treatment of Rectal Cancer
Berardino De Bari, M.D. is a radiation oncologist working in the radiation oncology dpt of Besançon (France). He has an academic position as Assistant Professor of the University of Bourgogne – Franche Comté (France) and of the University of Lausanne (Switzerland). His clinical and scientific interests are genitourinary and gastrointestinal cancers. He is a fellow of the European Society of Radiation Oncology (ESTRO) and he is teacher for ESTRO and for the International Atomic Energy Agency (IAEA). He is co-author of more than 95 articles and he is regularly invited as chair or speaker in national and international meetings.
From TBI to TMI for Advanced Onco-Hematological Diseases
Radiation Oncology Department, IRCCS Policlinico San Martino, Genova, Italy
Safe and Effective Stereotactic Body Radiation Therapy (SBRT) for High-Risk Prostate Cancer Patients: 4-year Outcomes of a Phase II Trial
Hear about the outcomes from a novel, extreme hypofractionated approach (SBRT) to prostate cancer treatment using TomoTherapy®
See more, do more with CTrue™ IR. Iterative Reconstruction Imaging for the Radixact® System
Jacob D. Shea is a Senior Research Scientist at Accuray Incorporated.
Feasibility of Real-Time Motion Management with Helical TomoTherapy
We are pleased to announce this manuscript has been selected to be highlighted under the Editors’ Choice column for the Medical Physics Scitation and medphys.org websites for the April 2018 issue.
TomoTherapy® with VoLO™ & TomoEDGE™: Special Considerations in Treatment Planning
Since its release, the TomoTherapy® platform has noticeably improved in its flexibility and efficiency of treatment planning. Within this newfound flexibility many of the original planning parameters are being reinvestigated in regard to their suitability, robustness, and efficiency of planning. This talk aims to open the discussion of planning on the TomoTherapy platform and help users understand how to efficiently arrive to where they want to be with their clinical dosimetry.
The Outcome of the First 100 Nasopharyngeal Cancer Patients in Thailand Treated by Helical TomoTherapy®
Dr. Chitapanarux has completed her MD and postdoctoral studies in Radiation Oncology from Chiang Mai University. She is the associate professor and the Deputy Head of Department of Radiology, Faculty of Medicine, Chiang Mai University. She is also the Head of Chiang Mai Cancer Registry. She has published more than 50 papers in reputed journals.
Clinical Outcomes of Several IMRT Techniques for Patients With Head and Neck Cancer: A Propensity Score-Weighted Analysis
Jean-Emmanuel Bibault, M.D., MSc
Georges-Pompidou European Hospital, France
Once Daily Accelerated Partial Breast Irradiation: Preliminary Results with Helical TomoTherapy®
Accelerated partial breast irradiation (APBI) is becoming an option for patients with low-risk breast cancer. The current practice is 38.5 Gy in 10 fractions b.i.d. over 5 days. This fractionation has a higher bioequivalent dose compared to the standard schedule. We report on preliminary results of once-daily APBI in patients treated with TomoTherapy®.
Fast Helical TomoTherapy in a Head and Neck Cancer Planning Study: Is Time Priceless?
The last few years, in radiotherapy there has been a growing focus on speed of treatment delivery (largely driven by economical and commercial interests). This study investigates the influence of treatment time on plan quality for helical tomotherapy (HT), using delivery times with Volumetric Modulated Arc Therapy (VMAT; Rapid Arc [RA]) as reference.
